Candel Therapeutics announced that the U.S. Food and Drug Administration, FDA, granted fast track designation for its lead asset CAN-2409, an investigational viral immunotherapy, plus valacyclovir in combination with pembrolizumab in order to improve survival or delay progression in patients with stage III/IV non-small cell lung cancer, NSCLC, who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy. "We are pleased with the FDA’s decision to grant fast track designation for CAN-2409, which reinforces our belief that our investigational medicine has meaningful potential to treat those living with late-stage lung cancer," said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. "Despite progress made in recent years, there remains a significant unmet need for patients with lung cancer who have an inadequate response to standard of care immune checkpoint inhibitors. Fast track designation is intended to bring promising medicines to patients sooner and the receipt of this designation by the FDA reinforces our belief that CAN-2409 has the potential to improve outcomes for patients who lack other treatment options."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CADL:
- Candel Therapeutics price target lowered to $7 from $8 at Credit Suisse
- Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
- Candel Therapeutics expects cash to fund operating plan into 2Q24
- Candel Therapeutics announces anticipated 2023 milestones
- Candel Therapeutics reports Q4 EPS (18c), consensus (31c)